

PACIFIC EDGE OPENS RETAIL OFFER FOR EXISTING SHAREHOLDERS

Cancer diagnostics business, Pacific Edge Limited (NZX/ASX: PEB), has today opened its retail offer which forms part of the capital raising announced to the market on 23 September 2021.

Eligible Shareholders in New Zealand are being offered the opportunity to participate in the Retail Offer, to raise up to a further NZ\$20 million (A\$19.4 million) (with the ability to accept oversubscriptions, subject to demand and at the discretion of the Board).

Each Eligible Shareholder will be entitled to apply for up to NZ\$50,000 of new shares under the Retail Offer. Shares will be offered at the lower of NZ\$1.35, being the price paid for shares under the Placement, and the volume weighted average price of Pacific Edge's shares on the NZX over the 5-day trading period up to and including the closing date of the retail offer (being 13 October 2021, unless extended).

The full terms of the Retail Offer are contained in the Retail Offer Document. This will be sent or made available to eligible New Zealand shareholders today (28 September 2021) and will also be available to those Eligible Shareholders online at <http://pacificedge.capitalraise.co.nz> from today. All Eligible Shareholders are encouraged to visit the website and apply online before the closing date at 5.00pm on Wednesday, 13 October 2021.

The new shares to be issued under the Retail Offer will rank equally in all respects with Pacific Edge's existing ordinary shares.

Key Dates

The record date for determining entitlements to participate in the Retail Offer was 5.00pm (NZST) on 22 September 2021.

- 28 September 2021: Opening Date – Retail Offer opens and offer document distributed to eligible shareholders
- 13 October 2021: Closing date - Retail Offer
- 20 October 2021: Settlement, allotment and trading of Retail Offer shares commences on NZX and ASX

ENDS

For more information contact: David Darling, Chief Executive Officer, Pacific Edge Ltd, P: +64 (3) 479 5800

For media assistance, please contact: Jackie Ellis, P: +64 27 246 2505 E: jackie@ellisandco.co.nz

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com

Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com

Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.